Anti-ADAM17 antibody [D1 (A12)] - BSA and Azide free (ab215268)

Overview

  • Product name
    Anti-ADAM17 antibody [D1 (A12)] - BSA and Azide free
    See all ADAM17 primary antibodies
  • Description
    Human monoclonal [D1 (A12)] to ADAM17 - BSA and Azide free
  • Tested applications
    Suitable for: Functional Studiesmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant fragment corresponding to Human ADAM17 (extracellular). (Ectodomain tagged to biotin).
    Database link: P78536

  • Positive control
    • TOV21G, IGROV-1, PC3 and HeLa cells stably over expressing HB-EGF-Alkaline Phosphatase.
  • General notes

    ADAM multidomain topology was exploited by first isolating an inhibitory human antibody (D1) that bound TACE-specific noncatalytic regions exclusively through its variable heavy (VH) domain. A D1-VH biased scFv phage-display library was then used to selectively isolate a new variable light (VL) chain that could simultaneously bind to the TACE catalytic domain. The resulting “cross-domain” human IgG1 antibody [D1(A12)] ab215268 is a previously undescribed biochemically holistic ADAM ectodomain inhibitor and demonstrates a unique alternative to small-molecule metalloprotease inhibition.

    Note from inventor: ab215268 is conformation sensitive and sees only a specific form of the native enzyme (reflecting its redox state). It does not work by IHC or WB. It was designed as a potential drug, active in native situations.

Properties

Applications

Our Abpromise guarantee covers the use of ab215268 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Functional Studies Use at an assay dependent concentration.

Target

  • Function
    Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Also involved in the activation of Notch pathway.
  • Tissue specificity
    Ubiquitously expressed. Expressed at highest levels in adult heart, placenta, skeletal muscle, pancreas, spleen, thymus, prostate, testes, ovary and small intestine, and in fetal brain, lung, liver and kidney.
  • Sequence similarities
    Contains 1 disintegrin domain.
    Contains 1 peptidase M12B domain.
  • Domain
    Must be membrane anchored to cleave the different substrates. The cytoplasmic domain is not required for the this activity. Only the catalytic domain is essential to shed TNF and p75 TNFR.
    The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
  • Post-translational
    modifications
    The precursor is cleaved by a furin endopeptidase.
    Phosphorylated. Stimulation by growth factor or phorbol 12-myristate 13-acetate induces phosphorylation of Ser-819 but decreases phosphorylation of Ser-791.
  • Cellular localization
    Membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • A disintegrin and metalloproteinase domain 17 (tumor necrosis factor, alpha, converting enzyme) antibody
    • A disintegrin and metalloproteinase domain 17 antibody
    • ADA17_HUMAN antibody
    • ADAM 17 antibody
    • ADAM metallopeptidase domain 17 antibody
    • ADAM17 antibody
    • ADAM17 protein antibody
    • CD 156b antibody
    • CD156b antibody
    • CD156b antigen antibody
    • CSVP antibody
    • Disintegrin and metalloproteinase domain-containing protein 17 antibody
    • MGC71942 antibody
    • NISBD antibody
    • NISBD1 antibody
    • Snake venom like protease antibody
    • Snake venom-like protease antibody
    • TACE antibody
    • TNF alpha convertase antibody
    • TNF alpha converting enzyme antibody
    • TNF-alpha convertase antibody
    • TNF-alpha-converting enzyme antibody
    • Tumor Necrosis Factor Alpha Converting Enzyme antibody
    see all

Images

  • Cancer cells with known expression of TACE substrates (TOV21G: TNF-α, IGROV1: TGF-α, PC3: AREG) and HeLa cells stably over expressing HB-EGF-Alkaline Phosphatase were used to assay cell-surface TACE activity. Each cell line was stimulated with PMA following a 1 h pretreatment with various concentrations of either ab215268, N-TIMP-3, or control human plasma IgG. Soluble TACE products were quantified from conditioned medium by sandwich ELISA or alkaline phosphatase activity. ab215268 consistently inhibited cell-surface TACE activity around fivefold more potently than N-TIMP-3.

References

ab215268 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab215268.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up